公开(公告)号：US08911958B2

公开(公告)日：2014-12-16

申请号：US14036018

申请日：2013-09-25

Applicant: MUSC Foundation for Research Development ,  Department of Veterans Affairs

Inventor： Maria F. Lopes-Virella ,  Gabriel T. Virella

IPC: G01N33/53 ,  G01N31/00 ,  G01N33/68 ,  G01N33/92

CPC classification number: G01N33/92 ,  G01N33/6893 ,  G01N2440/38 ,  G01N2800/042 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention relates to the analysis of modified LDL in the context of immune complexes. In particular, ox-LDL and AGE-LDL are shown to predict the development of coronary artery disease and other micro- and macrovascular disorders, particularly in the context of diabetes.

Abstract translation: 本发明涉及在免疫复合物的背景下对修饰的LDL的分析。 特别地，ox-LDL和AGE-LDL显示预测冠状动脉疾病和其他微血管和大血管疾病的发展，特别是在糖尿病的背景下。

公开(公告)号：US20140336574A1

公开(公告)日：2014-11-13

申请号：US14365269

申请日：2012-12-14

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Cephus Simmons ,  Rebecca Copenhaver DeLegge

IPC: A61M25/10 ,  A61M3/02

CPC classification number: A61M25/1011 ,  A61B10/02 ,  A61M3/0295 ,  A61M2025/1052 ,  A61M2025/1093 ,  A61M2210/1067

Abstract: A catheter including a plurality of balloons extending from the outer surface of the catheter that when inflated create a seal between the catheter and the patient's thereby eliminating leakage of fluids from around catheter during the procedure.

Abstract translation: 导管包括从导管的外表面延伸的多个气囊，当膨胀时，导管和患者之间形成密封，从而消除了在手术过程中导管周围的流体的泄漏。

公开(公告)号：US20140093974A1

公开(公告)日：2014-04-03

申请号：US14036018

申请日：2013-09-25

Applicant: DEPARTMENT OF VETERANS AFFAIRS ,  MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Maria F. LOPES-VIRELLA ,  Gabriel T. VIRELLA

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N33/6893 ,  G01N2440/38 ,  G01N2800/042 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention relates to the analysis of modified LDL in the context of immune complexes. In particular, ox-LDL and AGE-LDL are shown to predict the development of coronary artery disease and other micro- and macrovascular disorders, particularly in the context of diabetes.

Abstract translation: 本发明涉及在免疫复合物的背景下对修饰的LDL的分析。 特别地，ox-LDL和AGE-LDL显示预测冠状动脉疾病和其他微血管和大血管疾病的发展，特别是在糖尿病的背景下。

公开(公告)号：US20140037705A1

公开(公告)日：2014-02-06

申请号：US13900942

申请日：2013-05-23

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Walter George RENNE ,  Anthony Samuel MENNITO ,  Michael Gerard SCHMIDT ,  Jomprobe VUTHIGANON ,  George CHUMANOV

IPC: A61K33/34 ,  A61K6/00

CPC classification number: A61K33/34 ,  A61C5/70 ,  A61K6/0017 ,  A61K6/0023 ,  A61K6/007 ,  A61K6/0835 ,  C01G3/02 ,  C01G3/04 ,  C01G3/12 ,  Y10S977/773

Abstract: Provided are antibacterial and antimicrobial surface coatings and dental materials by utilizing the antimicrobial properties of copper chalcogenide and/or copper halide (CuQ, where Q=chalcogens including oxygen, or halogens, or nothing). An antimicrobial barrier is created by incorporation of CuQ nanoparticles of an appropriate size and at a concentration necessary and sufficient to create a unique bioelectrical environment. The unique bioelectrical environment results in biocidal effectiveness through a multi-factorial mechanism comprising a combination of the intrinsic quantum flux of copper (Cu0, Cu1+, Cu2+) ions and the high surface-to-volume electron sink facilitated by the nanoparticle. The result is the constant quantum flux of copper which manifests and establishes the antimicrobial environment preventing or inhibiting the growth of bacteria. The presence of CuQ results in inhibiting or delaying bacterial destruction and endogenous enzymatic breakdown of the zone of resin inter-diffusion, the integrity of which is essential for dental restoration longevity.

Abstract translation: 通过利用铜硫属化物和/或铜卤化物（CuQ，其中Q =包括氧或卤素的硫属元素，或任何物质）的抗微生物性质，提供抗菌和抗微生物表面涂层和牙科材料。 通过掺入适当尺寸的CuQ纳米颗粒并以必要和足够的浓度产生独特的生物电气环境来产生抗微生物屏障。 独特的生物电气环境通过包含铜（CuO，Cu1 +，Cu2 +）的固有量子通量和由纳米颗粒促进的高表面 - 体积电子吸收的组合的多因素机制产生杀生物效果。 结果是铜的恒定量子通量显示并建立了防止或抑制细菌生长的抗微生物环境。 CuQ的存在导致抑制或延迟细菌破坏和树脂互扩散区域的内源性酶分解，其完整性对于牙齿修复寿命至关重要。

公开(公告)号：US20250136983A1

公开(公告)日：2025-05-01

申请号：US18835880

申请日：2023-02-10

Applicant: MUSC Foundation for Research Development

Inventor： Hongkuan Fan

IPC: C12N15/113 ,  A61P25/28

Abstract: The invention provides compositions for modulating the level of Neat1 lncRNA and methods of using the compositions for treating neurodegenerative diseases or disorders.

公开(公告)号：US12234285B2

公开(公告)日：2025-02-25

申请号：US17112664

申请日：2020-12-04

Applicant: XOMA (US) LLC ,  MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Marina Roell ,  Mark Rubinstein ,  Hassan Issafras ,  Llewelyn Lao ,  Ou Li ,  Daniel H. Bedinger ,  Kristin Camfield Lind ,  Agnes Choppin Holmes ,  Toshihiko Takeuchi ,  Lauren Schwimmer ,  Hoa Giang ,  Amer M. Mirza ,  Kirk W. Johnson

IPC: C07K16/24 ,  A61K38/20 ,  A61K39/395 ,  A61P11/06 ,  A61P31/04 ,  A61P35/00 ,  A61P37/06 ,  C07K16/18 ,  C07K16/28 ,  A61K39/00 ,  C07K14/55

Abstract: The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.

公开(公告)号：US20240122986A1

公开(公告)日：2024-04-18

申请号：US18543191

申请日：2023-12-18

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Shikhar MEHROTRA ,  Shilpak CHATTERJEE

IPC: A61K35/17 ,  A61K9/00 ,  A61K35/26 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/24 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K9/0019 ,  A61K35/26 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  C07K16/249 ,  C07K16/2896 ,  C07K16/30 ,  C12N5/0636 ,  C12N5/0638 ,  C07K2317/55 ,  C07K2317/76 ,  C12N2501/15 ,  C12N2501/2301 ,  C12N2501/2306 ,  C12N2501/2312 ,  C12N2501/2323 ,  C12N2501/599

Abstract: The present disclosure provides methods of producing hybrid Th1/Th17 cells. Also provided herein are methods of treating cancer comprising targeting the CD38-mediated metabolic axis.

公开(公告)号：US11912755B2

公开(公告)日：2024-02-27

申请号：US17092539

申请日：2020-11-09

Applicant: iBio, Inc. ,  Novici Biotech LLC ,  MUSC Foundation for Research Development

Inventor： Carol Feghali-Bostwick ,  Terence E. Ryan ,  Hal S. Padgett ,  Matthew McGee

IPC: C07K14/78 ,  C12N15/82

CPC classification number: C07K14/78 ,  C12N15/8257 ,  C07K2319/036 ,  C07K2319/30 ,  A61K38/13 ,  A61K2300/00

Abstract: Materials and methods for using polypeptides containing fragments and variants of endostatin to treat fibrosis are described herein.

公开(公告)号：US20240032788A1

公开(公告)日：2024-02-01

申请号：US18191314

申请日：2023-03-28

Applicant: MUSC Foundation for Research Development

Inventor： Nancey Trevanian Tsai ,  Mark Evald Semler

IPC: A61B3/113 ,  A61B5/11 ,  A61B5/00 ,  A61B5/398 ,  A61B3/00 ,  A61B3/11 ,  A61B3/14

CPC classification number: A61B3/113 ,  A61B5/1103 ,  A61B5/4094 ,  A61B5/0077 ,  A61B5/398 ,  A61B3/0025 ,  A61B3/0033 ,  A61B3/0041 ,  A61B3/112 ,  A61B3/145 ,  A61B5/0059 ,  A61B5/162

Abstract: A device for measuring eye movement in a human subject comprises a housing, at least one stimulator mounted to the housing, and a sensor. The at least one stimulator is configured to provide stimulus to one or both eyes of the subject. The sensor is configured to collect information related to movement of one or both eyes of the subject. The device also includes a user interface that is configured to control the at least one stimulator and display information collected by the camera.

公开(公告)号：US11883430B2

公开(公告)日：2024-01-30

申请号：US16347743

申请日：2017-11-08

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Shikhar Mehrotra ,  Shilpak Chatterjee

IPC: A61K35/17 ,  A61P35/00 ,  A61K35/26 ,  C07K16/24 ,  C12N5/0783 ,  A61K45/06 ,  A61K9/00 ,  C07K16/28 ,  C07K16/30 ,  A61K39/395

CPC classification number: A61K35/17 ,  A61K9/0019 ,  A61K35/26 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  C07K16/249 ,  C07K16/2896 ,  C07K16/30 ,  C12N5/0636 ,  C12N5/0638 ,  C07K2317/55 ,  C07K2317/76 ,  C12N2501/15 ,  C12N2501/2301 ,  C12N2501/2306 ,  C12N2501/2312 ,  C12N2501/2323 ,  C12N2501/599 ,  A61K39/39558 ,  A61K2300/00

Abstract: The present disclosure provides methods of producing hybrid Th1/Th17 cells. Also provided herein are methods of treating cancer comprising targeting the CD38-mediated metabolic axis.